Development of a Structural Model for NF-κB Inhibition of Sesquiterpene Lactones Using Self-Organizing Neural Networks.

Development of a Structural Model for NF-κB Inhibition of Sesquiterpene Lactones Using Self-Organizing Neural Networks.

Wagner S, Hofmann A, Siedle B, Terfloth L, Merfort I, Gasteiger J. “Development of a Structural Model for NF-κB Inhibition of Sesquiterpene Lactones Using Self-Organizing Neural Networks.” J. Med. Chem.. 2006;49(7):2241-2252.

TitleDevelopment of a Structural Model for NF-κB Inhibition of Sesquiterpene Lactones Using Self-Organizing Neural Networks
Publication TypeJournal Article
Year of Publication2006
AuthorsWagner S, Hofmann A, Siedle B, Terfloth L, Merfort I, Gasteiger J
JournalJ. Med. Chem.
Volume49
Issue7
Pagination2241 – 2252
Date Published04/2006
ISSN0022-2623
AbstractA variety of sesquiterpene lactones (SLs) possess considerable anti-inflammatory activity. Several studies have shown that they exert this effect in part by inhibiting the activation of the transcription factor NF-κB. In the present study we elaborated on the investigation of a data set of 103 structurally diverse SLs for which we had previously developed several different QSAR equations dependent on the skeletal type. Use of 3D structure descriptors resulted in a single model for the entire data set. In particular, local radial distribution functions (L-RDF) were used that centered on the methylene−carbonyl substructure believed to be the site of attack of cysteine-38 of the p65/NF-κB subunit. The model was developed by using a counterpropagation neural network (CPGNN), attesting to the power of this method for establishing structure−activity-relationships. The investigations shed more light onto the influence of the chemical structure on NF-κB inhibitory activity.
DOI10.1021/jm051125n
Short TitleJ. Med. Chem.

We use cookies on our website to enhance the user experience and to analyze traffic. We may share your site usage data with our analytics software providers. By clicking “Accept & Close,” you are consenting to the terms described on our Disclaimer page.